BiotechTube

AXS-05 + Bupropion + Placebo

Phase 2/3Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Agitation in Patients With Dementia of the Alzheimer's Type

Conditions

Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor

Trial Timeline

Jul 13, 2017 → Apr 17, 2020

NCT ID
NCT03226522

About AXS-05 + Bupropion + Placebo

AXS-05 + Bupropion + Placebo is a phase 2/3 stage product being developed by Axsome Therapeutics for Agitation in Patients With Dementia of the Alzheimer's Type. The current trial status is completed. This product is registered under clinical trial identifier NCT03226522. Target conditions include Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor.

What happened to similar drugs?

2 of 14 similar drugs in Agitation in Patients With Dementia of the Alzheimer's Type were approved

Approved (2) Terminated (2) Active (10)
✅Quetiapine + Haloperidol + Lorazepam + CogentinAstraZenecaApproved
🔄Brexpiprazole, OPC-34712LundbeckPhase 3
🔄Brexpiprazole, OPC-34712 + Placebo Oral TabletLundbeckPhase 3
🔄BrexpiprazoleLundbeckPhase 3
🔄AXS-05 (dextromethorphan-bupropion) + PlaceboAxsome TherapeuticsPhase 3
❌AXS-05 (dextromethorphan-bupropion)Axsome TherapeuticsPhase 3
🔄AXS-05 + PlaceboAxsome TherapeuticsPhase 3

Hype Score Breakdown

Clinical
15
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03226522Phase 2/3Completed

Competing Products

20 competing products in Agitation in Patients With Dementia of the Alzheimer's Type

See all competitors
ProductCompanyStageHype Score
ONO-2020 + PlaceboOno PharmaceuticalPhase 2
42
Quetiapine + Haloperidol + Lorazepam + CogentinAstraZenecaApproved
43
Brexpiprazole, OPC-34712LundbeckPhase 3
37
Brexpiprazole, OPC-34712 + Placebo Oral TabletLundbeckPhase 3
37
BrexpiprazoleLundbeckPhase 3
37
AXS-05 (dextromethorphan-bupropion) + PlaceboAxsome TherapeuticsPhase 3
37
AXS-05 (dextromethorphan-bupropion)Axsome TherapeuticsPhase 3
29
AXS-05 + PlaceboAxsome TherapeuticsPhase 3
37
AXS-05 + PlaceboAxsome TherapeuticsPhase 3
37
Pimavanserin 34 mg + Pimavanserin 20 mgAcadia PharmaceuticalsPhase 2
24
PimavanserinAcadia PharmaceuticalsPhase 2
32
Sublingual film containing Dexmedetomidine (BXCL501) + Placebo FilmBioXcel TherapeuticsPhase 3
30
BXCL501 + Matching PlaceboBioXcel TherapeuticsPhase 3
22
Sublingual film containing BXCL501 (Dexmedetomidine) + Placebo filmBioXcel TherapeuticsPhase 1
19
BXCL501 + Matching PlaceboBioXcel TherapeuticsPhase 3
30
BXCL501 + Matching PlaceboBioXcel TherapeuticsPhase 3
30
Sublingual film containing dexmedetomidine (BXCL501) + Placebo FilmBioXcel TherapeuticsPhase 3
30
BXCL501 + BXCL501 + Placebo filmBioXcel TherapeuticsPhase 2
17
BXCL501 + Placebo filmBioXcel TherapeuticsPhase 2
17
Sublingual film containing Dexmedetomidine + Sublingual Placebo FilmBioXcel TherapeuticsPhase 1/2
22